Günther, Andreas

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1

Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., Abeliovich, H., Abildgaard, M. H., Abudu, Y. P., Acevedo-Arozena, A., et al. (2021) · Autophagy

Autophagy in Disease and TherapyCalcium signaling and nucleotide metabolism

Cited by 2,897

WNT1-inducible signaling protein–1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis

Königshoff, M., Kramer, M., Balsara, N., Wilhelm, J., Amarie, O. V., Jahn, A., Rose, F., Fink, L., Seeger, W., Schaefer, L., et al. (2009) · Journal of Clinical Investigation

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 558

Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema

Günther, A., Siebert, C., Schmidt, R., Ziegler, S., Grimminger, F., Yabut, M., Temmesfeld, B., Walmrath, D., Morr, H., & Seeger, W. (1996) · American Journal of Respiratory and Critical Care Medicine

Respiratory Support and MechanismsNeonatal Respiratory Health Research

Cited by 417

Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo

Lehmann, M., Korfei, M., Mutze, K., Klee, S., Skronska-Wasek, W., Alsafadi, H. N., Ota, C., Costa, R., Schiller, H. B., Lindner, M., et al. (2017) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisTelomeres, Telomerase, and Senescence

Cited by 403

Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis

El Agha, E., Moiseenko, A., Kheirollahi, V., De Langhe, S., Crnkovic, S., Kwapiszewska, G., Szibor, M., Kosanovic, D., Schwind, F., Schermuly, R. T., et al. (2017) · Cell Stem Cell

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 347

Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Behr, J., Bendstrup, E., Crestani, B., Günther, A., Olschewski, H., Sköld, C. M., Wells, A., Wuyts, W., Koschel, D., Kreuter, M., et al. (2016) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 146

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

Cottin, V., Koschel, D., Günther, A., Albera, C., Azuma, A., Sköld, C. M., Tomassetti, S., Hormel, P., Stauffer, J. L., Strombom, I., et al. (2018) · ERJ Open Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPharmacovigilance and Adverse Drug Reactions

Cited by 121

Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study

Molyneaux, P. L., Hirani, N. A., Chia, C. C. K., Kulkarni, T., Zaman, T., Kaner, R. J., Coelho, A. L., Jannini-Sa, Y. A. P., Windsor, B., Kruger, S., et al. (2026) · Nature Communications

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 1